絞り込み

16641

広告

「医療マンガ大賞」、受賞作品が決定 (日経BP)

神奈川県横浜市は今年、医療広報の一環として、漫画を活用した取り組み「医療マンガ大賞」を創設した(関連記事:医師と患者のギャップを埋める「医療マンガ大賞」創設)。...

  1. タイの大型肉食恐竜、新種と判明 (デイリ...
  2. 映画を通じた交流を 大阪韓国映画祭始まる...
  3. だんだん小さく、やがて視野の外…「さよな...
  4. 新種の大型肉食恐竜「シャムラプトル・スワ...

ニュース一覧

The anti-PLA2R antibody in membranous nephropathy: what we know and what remains a decade after its discovery.

著者 van de Logt AE , Fresquet M , Wetzels JF , Brenchley P
Kidney Int.2019 Aug 12 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (5view , 0users)

Full Text Sources

The discovery in 2009 of the M-type phospholipase A2 receptor (PLA2R) as the primary target in membranous nephropathy (MN) greatly advanced basic and clinical research. Primary MN is now considered a renal-limited autoimmune disease, with antibodies against PLA2R (aPLA2Rab) identified in 70-80 % of patients of various ethnic groups. Although the use of aPLA2Rab as a diagnostic and prognostic biomarker is now widely accepted, many questions related to the development of the auto-immune response, the role of IgG subclasses and antigenic epitopes, and the pathways to podocyte injury remain unresolved. PLA2R-associated MN most likely develops governed by factors such as genetic susceptibility, loss of tolerance, alterations in antigen expression with a role for environmental factors like air pollution, smoking, and infections. More detailed knowledge of genetic factors, the relevant B- and T-cell epitopes, and the mechanisms of podocyte injury is needed to identify patients at risk for disease progression and to develop optimized, targeted treatment strategies. In this review we highlight unresolved issues, addressing initiation of antibody formation, the timeline of antibody production, the role of IgG subclass, and the pathogenicity of the antibodies in concert with complement to produce glomerular pathology and proteinuria.
PMID: 31611068 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード